Steven A. Cohen is a well-known billionaire investor, and his disclosure of an 8.9% passive stake in Praxis Precision Medicines (PRAX) may be seen as a vote of confidence in the company's prospects. This could lead to increased investor interest and a potential short-term positive impact on the stock price.